Metoclopramide Hydrochloride Accord Healthcare

Metoclopramide Hydrochloride, the active ingredient in Metoclopramide Hydrochloride Accord Healthcare, is a dopamine antagonist presented as an oral dosage form for oral use. It is employed to manage nausea, vomiting, gastroparesis, and functional dyspepsia in adult patients under medical supervision.

GNH USA supplies Metoclopramide Hydrochloride Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures timely delivery across Europe, Asia, Africa and the Americas.

Metoclopramide Hydrochloride is used to treat conditions involving impaired gastrointestinal motility or emesis.

- Nausea and vomiting: reduces the frequency and severity of acute and chemotherapy‑induced nausea. - Gastroparesis: enhances gastric emptying and alleviates related symptoms. - Functional dyspepsia: improves post‑prandial discomfort and early satiety. - Post‑operative nausea: helps control nausea after surgical procedures.

Metoclopramide Hydrochloride may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or agitation - Diarrhea - Dry mouth - Headache

Serious or Rare Side Effects: - Extrapyramidal reactions such as dystonia, akathisia, or parkinsonism - Neuroleptic malignant syndrome, a life‑threatening condition - Tardive dyskinesia, especially with prolonged use

Before prescribing Metoclopramide Hydrochloride, clinicians should consider several safety factors.

- Assess renal function: adjust use in severe renal impairment. - Avoid in patients with known hypersensitivity to metoclopramide. - Monitor for signs of depression or suicidal thoughts. - Use caution in elderly: higher risk of extrapyramidal effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metoclopramide Hydrochloride can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticholinergic agents: may diminish the pro‑kinetic effect. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Other dopamine antagonists: additive risk of extrapyramidal symptoms. - Drugs that prolong the QT interval: monitor cardiac rhythm during co‑administration.